Potential Utility of Radiopharmaceuticals in the Battle Against SARSCov- 2 and COVID-19 Pandemic
- PMID: 34635047
- DOI: 10.2174/1874471014666211011122250
Potential Utility of Radiopharmaceuticals in the Battle Against SARSCov- 2 and COVID-19 Pandemic
Abstract
Coronavirus disease 2019 (COVID-19) pandemic, which has emerged in December 2019 in the city of Wuhan, China, has significantly affected healthcare systems and economies within a short timeframe. Treatment strategies offer alleviation of symptoms in the absence of commercially available specific antiviral agents. Within this context, the introduction of innovative therapeutic approaches against the SARS-CoV-2 virus is a critical need that should be addressed urgently. The anti-inflammatory effect of low dose irradiation has been proposed as a potential therapeutic strategy for COVID-19 pneumonia. Consideration of external beam irradiation for management of COVID-19 pneumonia has prompted the investigation of alternative methods of irradiation with potentially improved toxicity profiles. Theoretically, targeted radiotherapy may have several advantages over conventional external beam radiotherapy owing to the capability to deliver effective radiation doses without adverse irradiation effects. Since radionuclides are conjugated to targeting vectors, such as antibodies and cell surface receptor binding peptides, irradiation may be focused on targeted cells with optimal sparing of surrounding normal tissues. In the context of COVID-19 management, targeted irradiation is expected to compromise SARS-CoV-2 extracellular virions. Targeted radiotherapy may offer a viable means of combating against SARS-CoV-2 virus. There is room for improvement with the need for efficacy, feasibility, and toxicity studies. Although targeted radiotherapy itself may not achieve absolute eradication of virus or virus-infected cells, it may at least serve as a supplementary therapeutic strategy that could be utilized in combination with other antiviral treatments. Further investigations focusing on nuclear medicine, radiopharmaceuticals, and targeted radiotherapy strategies may pave the way for the development of efficacious antiviral treatments which may be utilized in the battle against the current COVID-19 pandemic.
Keywords: COVID-19; Radiopharmaceutical; SARS-CoV-2; coronavirus; pandemic; targeted radiotherapy.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic.Curr Med Chem. 2021;28(15):2852-2886. doi: 10.2174/0929867327666200702151018. Curr Med Chem. 2021. PMID: 32614740
-
Nanotechnology and COVID-19 Convergence: Toward New Planetary Health Interventions Against the Pandemic.OMICS. 2022 Sep;26(9):473-488. doi: 10.1089/omi.2022.0072. Epub 2022 Aug 30. OMICS. 2022. PMID: 36040392 Review.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets.Viral Immunol. 2021 Oct;34(8):510-521. doi: 10.1089/vim.2021.0023. Epub 2021 May 20. Viral Immunol. 2021. PMID: 34018828
-
Herbal Medicines to Fight Against COVID-19: New Battle with an Old Weapon.Curr Pharm Biotechnol. 2022;23(2):235-260. doi: 10.2174/1389201022666210322124348. Curr Pharm Biotechnol. 2022. PMID: 33749558 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous